Hemogenyx Pharmaceuticals (LON:HEMO) Stock Price Down 35.6% – Time to Sell?

Hemogenyx Pharmaceuticals Plc (LON:HEMO)’s share price dropped 35.6% on Tuesday . The stock traded as low as GBX 192.59 ($2.50) and last traded at GBX 196.80 ($2.55). Approximately 88,716 shares changed hands during mid-day trading, an increase of 404% from the average daily volume of 17,615 shares. The stock had previously closed at GBX 305.50 ($3.96).

Hemogenyx Pharmaceuticals Stock Down 0.5 %

The company has a current ratio of 4.38, a quick ratio of 6.72 and a debt-to-equity ratio of 90.87. The business has a fifty day moving average of GBX 348.35 and a two-hundred day moving average of GBX 157.34. The company has a market cap of £6.62 million, a price-to-earnings ratio of -950.47 and a beta of 3.14.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.